<SEC-DOCUMENT>0000721371-15-000047.txt : 20150605
<SEC-HEADER>0000721371-15-000047.hdr.sgml : 20150605
<ACCEPTANCE-DATETIME>20150605090338
ACCESSION NUMBER:		0000721371-15-000047
CONFORMED SUBMISSION TYPE:	8-K/A
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150605
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150605
DATE AS OF CHANGE:		20150605

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CARDINAL HEALTH INC
		CENTRAL INDEX KEY:			0000721371
		STANDARD INDUSTRIAL CLASSIFICATION:	WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
		IRS NUMBER:				310958666
		STATE OF INCORPORATION:			OH
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11373
		FILM NUMBER:		15914525

	BUSINESS ADDRESS:	
		STREET 1:		7000 CARDINAL PLACE
		CITY:			DUBLIN
		STATE:			OH
		ZIP:			43017
		BUSINESS PHONE:		6147573033

	MAIL ADDRESS:	
		STREET 1:		7000 CARDINAL PLACE
		CITY:			DUBLIN
		STATE:			OH
		ZIP:			43017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CARDINAL DISTRIBUTION INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K/A
<SEQUENCE>1
<FILENAME>june2015form8-ka.htm
<DESCRIPTION>AMENDMENT NO. 1 TO CURRENT REPORT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>June 2015 Form 8-K/A</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s497FEB571E5625CD9AC1C38230882991"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:4px;text-align:center;font-size:14pt;"><font style="font-family:Arial Narrow;font-size:14pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:Arial Narrow;font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:Arial Narrow;font-size:14pt;font-weight:bold;">WASHINGTON, DC 20549</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:18pt;"><font style="font-family:Arial Narrow;font-size:18pt;font-weight:bold;">FORM 8-K/A</font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:Arial Narrow;font-size:14pt;font-weight:bold;">(Amendment No. 1)</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:14pt;"><font style="font-family:Arial Narrow;font-size:14pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial Narrow;font-size:12pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d) of the</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial Narrow;font-size:12pt;font-weight:bold;">Securities Exchange Act of 1934</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Arial Narrow;font-size:12pt;font-weight:bold;">Date of Report (Date of earliest event reported): June 5, 2015</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:24pt;"><font style="font-family:Arial Narrow;font-size:24pt;font-weight:bold;">Cardinal Health, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;font-weight:bold;">(Exact Name of Registrant as Specified in Charter)</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="32%"></td><td width="3%"></td><td width="31%"></td><td width="3%"></td><td width="31%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;font-weight:bold;">Ohio</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;font-weight:bold;">1-11373</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;font-weight:bold;">31-0958666</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">(State or Other Jurisdiction</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">of Incorporation)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">(Commission</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">File Number)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">(IRS Employer</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;font-weight:bold;">7000 Cardinal Place, Dublin, Ohio 43017</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">(Address of Principal Executive Offices) (Zip Code)</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;font-weight:bold;">(614) 757-5000</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</font><font style="font-family:Arial Narrow;font-size:10pt;font-style:italic;">see</font><font style="font-family:Arial Narrow;font-size:10pt;">&#32;General Instruction A.2. below):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="6%"></td><td width="94%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="6%"></td><td width="94%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="6%"></td><td width="94%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="6%"></td><td width="94%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sA179353E32B5A237B142C38230BA0CD0"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;font-weight:bold;">EXPLANATORY NOTE</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">This amendment to Form 8-K is being furnished herewith for the purpose of correcting an error in the news release issued by Cardinal Health, Inc. (the "Company") on June 5, 2015 announcing the acquisition of The Harvard Drug Group.  In the news release, the sixth paragraph, second sentence, should read "This range is based on the assumptions . . . that the previously announced Cordis acquisition closes in the United States and key non-U.S. countries towards the end of calendar 2015." rather than "This range is based on the assumptions . . . that the previously announced Cordis acquisition closes in the United States and key non-U.S. countries towards the end of calendar 2016." as originally issued inadvertently.  A copy of the complete, corrected news release is included as Exhibit 99.1 to this report.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial Narrow;font-size:10pt;font-weight:bold;">Item 9.01</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;font-weight:bold;">Financial Statements and Exhibits. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">(d)&#160; </font><font style="font-family:Arial Narrow;font-size:10pt;font-style:italic;">Exhibits</font><font style="font-family:Arial Narrow;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td width="14%"></td><td width="1%"></td><td width="1%"></td><td width="28%"></td><td width="28%"></td><td width="28%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">Corrected news release issued by the Company on June 5, 2015</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><a name="sA179353E32B5A237B142C38230BA0CD0"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td width="42%"></td><td width="3%"></td><td width="5%"></td><td width="2%"></td><td width="4%"></td><td width="3%"></td><td width="41%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">Cardinal Health, Inc.</font></div><div style="font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">(Registrant)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">Date: June 5, 2015</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">By:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">/s/ Stuart G. Laws</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">Name:  Stuart G. Laws</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">Title:  Senior Vice President and Chief Accounting Officer</font></div></td></tr></table></div></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><a name="sA179353E32B5A237B142C38230BA0CD0"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;font-weight:bold;">EXHIBIT INDEX</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td width="14%"></td><td width="1%"></td><td width="1%"></td><td width="28%"></td><td width="28%"></td><td width="28%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">Corrected news release issued by the Company on June 5, 2015</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">4</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit991correctednewsrel.htm
<DESCRIPTION>CORRECTED NEWS RELEASE
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>Exhibit 99.1 Corrected News Release</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s25FB8943ECADD4E68882C382315F73CB"></a><div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Exhibit 99.1</font></div></div><br><div style="line-height:120%;text-align:center;text-indent:96px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.65625%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="20%"></td><td width="20%"></td><td width="20%"></td><td width="20%"></td><td width="20%"></td></tr><tr><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">For Immediate Release</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;"><img src="logoa02a01.jpg" style="height:64px;width:196px;"></div></td></tr></table></div><font style="font-family:Arial;font-size:11pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td width="2%"></td><td width="8%"></td><td width="37%"></td><td width="7%"></td><td width="11%"></td><td width="33%"></td><td width="2%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #ee2724;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #ee2724;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #ee2724;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #ee2724;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #ee2724;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #ee2724;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #ee2724;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Media:</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Debbie Mitchell</font></div><div style="font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">(614) 757-6225</font></div><div style="font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">debbie.mitchell@cardinalhealth.com</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Investors:</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Sally Curley</font></div><div style="font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">(614) 757-7115</font></div><div style="font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">sally.curley@cardinalhealth.com</font></div><div style="font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">CARDINAL HEALTH TO ACQUIRE THE HARVARD DRUG GROUP </font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">FOR $1.115 BILLION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:22px;"><font style="font-family:Arial;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Acquisition of $450 million pharmaceutical distributor increases generics scale and reach </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:22px;"><font style="font-family:Arial;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Non-GAAP</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">&#32;diluted earnings per share from continuing operations accretion expected to be greater than $0.15 in fiscal 2016, more than $0.20 in fiscal 2017; accretion expected to be increasingly greater thereafter</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:22px;"><font style="font-family:Arial;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Preliminary expectation for Cardinal Health</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8217;</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">s fiscal 2016 non-GAAP diluted earnings per share from continuing operations is $4.75 to $5.05; date for fourth-quarter fiscal 2015 earnings and fiscal 2016 guidance announced</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:22px;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Webcast scheduled for 10:10 a.m. Eastern</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">DUBLIN, Ohio, June 5, 2015 &#8212; Cardinal Health today announced plans to acquire The Harvard Drug Group (THDG), a distributor of generic pharmaceuticals, over-the-counter medications and related products to retail, institutional and alternate care customers. THDG is currently owned by Court Square Capital Partners.  Cardinal Health will pay $1.115 billion using existing cash and new debt.  The transaction is expected to close in the beginning of fiscal year 2016 subject to regulatory approvals and other customary closing conditions.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Assuming this timing, Cardinal Health expects accretion in non-GAAP diluted earnings per share (EPS) from continuing operations of greater than $0.15 per share in fiscal 2016, net of the $0.03 to $0.04 per share of interest expense for the related debt financing.  Cardinal Health expects accretion in non-GAAP diluted EPS of more than $0.20 in fiscal 2017 and for accretion to be increasingly greater thereafter. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">In addition to enhancing the company</font><font style="font-family:inherit;font-size:11pt;">&#8217;</font><font style="font-family:Arial;font-size:11pt;">s generic pharmaceutical distribution business, the acquisition expands Cardinal Health</font><font style="font-family:inherit;font-size:11pt;">&#8217;</font><font style="font-family:Arial;font-size:11pt;">s existing telesales programs and capabilities; broadens the company</font><font style="font-family:inherit;font-size:11pt;">&#8217;</font><font style="font-family:Arial;font-size:11pt;">s portfolio of over-the counter pharmaceutical products; and brings specialized packaging offerings to meet the needs of hospital systems and other institutions.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Headquartered in Livonia, Mich., The Harvard Drug Group had revenues of approximately $450 million in 2014. There are 450 employees and two distribution facilities included in the transaction.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">&#8220;The Harvard Drug Group aligns perfectly with our commitment to provide the most comprehensive line of pharmaceutical products for the broadest range of customers,&#8221; said George Barrett, chairman and chief executive officer of Cardinal Health. &#8220;This acquisition enhances our ability to support retail and institutional customers and further utilizes Red Oak, our joint venture with CVS Health to source generics.&#8221;  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">FY16 Earnings Guidance</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">As a result of this planned acquisition and the</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:Arial;font-size:11pt;">pending acquisition of Cordis, Cardinal Health is providing its preliminary expectations for fiscal 2016 non-GAAP diluted EPS from continuing operations of $4.75 to </font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s25FB8943ECADD4E68882C382315F73CB"></a><div></div><br><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">$5.05.  This range is based on the assumptions that the THDG transaction closes in the first quarter of fiscal 2016 and that the previously announced Cordis acquisition closes in the United States and key non-U.S. countries towards the end of calendar 2015.  The company expects to issue $1.5 billion of new debt related to these two acquisitions.  The company expects to discuss its fiscal year 2016 financial outlook in detail on its fourth quarter fiscal 2015 earnings call scheduled for July 30, 2015.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Webcasted events</font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Cardinal Health will webcast its Dublin Day Investor/Analyst meeting from 10:10 a.m. to 11:00 a.m. Eastern today, during which its executives will discuss the matters referenced in this release. To access the call, participants can dial 855-241-2663 and use conference ID 7246584.  To access the webcast and a corresponding slide presentation and Frequently Asked Question &amp; Answer document, go to the Investors page at </font><font style="font-family:Arial;font-size:11pt;text-decoration:underline;">ir.cardinalhealth.com</font><font style="font-family:Arial;font-size:11pt;">.  Presentation slides and an audio replay will be archived on the website after the conclusion of the meeting.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">In addition, Cardinal Health will be presenting at the Goldman Sachs 36th Annual Global Healthcare</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:Arial;font-size:11pt;">Conference on Wednesday, June 10 at 10:00 a.m. Pacific time in Rancho Palos Verdes, Calif.   </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">The company plans to release fourth-quarter and full year fiscal 2015 financial results and fiscal year 2016 guidance on Thursday, July 30, 2015 prior to the opening of trading on the New York Stock Exchange.  A webcast and conference call has been scheduled for July 30 at 8:30 a.m. Eastern to discuss the results and guidance.  The call and corresponding slide presentation can be accessed by going to the Investors page at </font><font style="font-family:Arial;font-size:11pt;text-decoration:underline;">ir.cardinalhealth.com</font><font style="font-family:Arial;font-size:11pt;">&#32;or by dialing 913-312-1448 and using passcode 5598613.&#160; There is no pre-registration for the call. Participants are advised to dial into the call at least 10 minutes prior to the start time.  Presentation slides and an audio replay will be archived on the Cardinal Health website after the conclusion of the meeting. The replay will be available until Thursday, Aug. 6, 2015 and by dialing 719-457-0820 and using passcode 5598613.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">NON-GAAP FINANCIAL MEASURES (INCLUDING FOOTNOTE)</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Footnote (1) Non-GAAP diluted earnings per share from continuing operations: (A) earnings from continuing operations, &#160;excluding (1) restructuring and employee severance, (2) amortization and other acquisition-related costs, (3) impairments and (gain)/loss on disposal of assets, (4) litigation (recoveries)/charges, net, (5) LIFO charges/(credits), and (6) loss on extinguishment of debt, each net of tax, (B) divided by diluted weighted average shares outstanding. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Cardinal Health presents non-GAAP diluted earnings per share from continuing operations on a forward-looking basis. The most directly comparable forward-looking GAAP measure is diluted earnings per share from continuing operations. Cardinal Health is unable to provide a quantitative reconciliation of this forward-looking non-GAAP measure to the most directly comparable forward-looking GAAP measure, because Cardinal Health cannot reliably forecast restructuring and employee severance, amortization and acquisition-related costs (which Cardinal Health expects to increase significantly as a result of pending acquisitions), impairments and (gain)/loss on disposal of assets, litigation (recoveries)/charges, net, and LIFO charges/(credits), which are difficult to predict and estimate. Please note that the unavailable reconciling items could significantly impact Cardinal Health's future financial results. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">About Cardinal Health </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is a $91 billion </font><font style="font-family:Arial;font-size:11pt;text-decoration:underline;">health care services company</font><font style="font-family:Arial;font-size:11pt;">&#32;that improves the cost-effectiveness of health care. Cardinal Health helps </font><font style="font-family:Arial;font-size:11pt;text-decoration:underline;">pharmacies</font><font style="font-family:Arial;font-size:11pt;">, </font><font style="font-family:Arial;font-size:11pt;text-decoration:underline;">hospitals</font><font style="font-family:Arial;font-size:11pt;">, </font><font style="font-family:Arial;font-size:11pt;text-decoration:underline;">ambulatory surgery centers, clinical laboratories</font><font style="font-family:Arial;font-size:11pt;">&#32;</font><font style="font-family:Arial;font-size:11pt;">and </font><font style="font-family:Arial;font-size:11pt;text-decoration:underline;">physician offices</font><font style="font-family:Arial;font-size:11pt;">&#32;focus on patient care while </font><font style="font-family:Arial;font-size:11pt;text-decoration:underline;">reducing costs, enhancing efficiency and improving quality</font><font style="font-family:Arial;font-size:11pt;">. Cardinal Health is an essential link in the health care supply chain, providing </font><font style="font-family:Arial;font-size:11pt;text-decoration:underline;">pharmaceuticals</font><font style="font-family:Arial;font-size:11pt;">&#32;and </font><font style="font-family:Arial;font-size:11pt;text-decoration:underline;">medical products</font><font style="font-family:Arial;font-size:11pt;">&#32;and services to more than 100,000 locations each day and is also the industry-leading direct-to-home medical supplies distributor. The company is a leading manufacturer of medical and surgical products, including </font><font style="font-family:Arial;font-size:11pt;text-decoration:underline;">gloves</font><font style="font-family:Arial;font-size:11pt;">, </font><font style="font-family:Arial;font-size:11pt;text-decoration:underline;">surgical apparel</font><font style="font-family:Arial;font-size:11pt;">&#32;</font><font style="font-family:Arial;font-size:11pt;">and </font><font style="font-family:Arial;font-size:11pt;text-decoration:underline;">fluid management</font><font style="font-family:Arial;font-size:11pt;">&#32;products. In addition, the company operates the nation's largest </font><font style="font-family:Arial;font-size:11pt;text-decoration:underline;">network of radiopharmacies</font><font style="font-family:Arial;font-size:11pt;">&#32;that dispense products to aid in the early diagnosis and treatment of disease. Ranked </font></div><br><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">2</font></div></div><hr style="page-break-after:always"><a name="s25FB8943ECADD4E68882C382315F73CB"></a><div></div><br><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">#22 on the Fortune 500, Cardinal Health </font><font style="font-family:Arial;font-size:11pt;text-decoration:underline;">employs 34,000 people</font><font style="font-family:Arial;font-size:11pt;">&#32;worldwide. More information about the company may be found at </font><font style="font-family:Arial;font-size:11pt;text-decoration:underline;">www.cardinalhealth.com</font><font style="font-family:Arial;font-size:11pt;">&#32;and </font><font style="font-family:Arial;font-size:11pt;text-decoration:underline;">CardinalHealth</font><font style="font-family:Arial;font-size:11pt;">&#32;on Twitter.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Cautions Concerning Forward-Looking Statements</font><font style="font-family:Arial;font-size:11pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">This release contains forward-looking statements addressing Cardinal Health's plans to acquire The Harvard Drug Group (THDG) and other statements about future expectations, prospects, estimates and other matters that are dependent upon future events or developments. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook and expense accruals. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These risks and uncertainties include:</font><font style="font-family:inherit;font-size:11pt;">&#160;</font><font style="font-family:Arial;font-size:11pt;">&#32;the ability to successfully complete the acquisitions of The Harvard Drug Group and Cordis on a timely basis, including receipt of required regulatory approvals and satisfaction of other conditions; the ability to retain customers and employees of the acquired businesses and to successfully integrate the acquired businesses into Cardinal Health's operations, if the acquisitions are completed; the ability to achieve the expected synergies as well as accretion in earnings; competitive pressures in Cardinal Health's various lines of business; the ability to achieve the expected benefits from the generic sourcing venture with CVS Health; the frequency or rate of pharmaceutical price appreciation or deflation and the timing of generic and branded pharmaceutical introductions; the non-renewal or a default under one or more key customer or supplier arrangements or changes to the terms of or level of purchases under those arrangements; uncertainties due to government health care reform including federal health care reform legislation; changes in the distribution patterns or reimbursement rates for health care products and services; the effects of any investigation or action by any regulatory authority; and changes in the cost of commodities such as oil-based resins, cotton, latex and diesel fuel. Cardinal Health is subject to additional risks and uncertainties described in Cardinal Health's Form 10-K, Form 10-Q and Form 8-K reports and exhibits to those reports. This release reflects management's views as of June 5, 2015.</font><font style="font-family:inherit;font-size:11pt;">&#160;</font><font style="font-family:Arial;font-size:11pt;">&#32;Except to the extent required by applicable law, Cardinal Health undertakes no obligation to update or revise any forward-looking statement.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">3</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logoa02a01.jpg
<TEXT>
begin 644 logoa02a01.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X0!.17AI9@``34T`*@````@`!`,!``4`
M```!````/E$0``$````!`0```%$1``0````!```N(%$2``0````!```N(```
M`````8:@``"QB/_;`$,`"`8&!P8%"`<'!PD)"`H,%`T,"PL,&1(3#Q0=&A\>
M'1H<'"`D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T,O_;`$,!"0D)#`L,
M&`T-&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,O_``!$(`/0"XP,!(@`"$0$#$0'_Q``?```!!0$!`0$!
M`0```````````0(#!`4&!P@)"@O_Q`"U$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q``?`0`#`0$!`0$!`0$!````````
M`0(#!`4&!P@)"@O_Q`"U$0`"`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1
M!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ
M0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25
MEI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3E
MYN?HZ>KR\_3U]O?X^?K_V@`,`P$``A$#$0`_`/?Z*Q#XD6$XN])U:V&2"3:F
M4+@=28B_%)'XQ\.R/L;5[:%]N[;<,83CZ/BH]I#N=/U.O:Z@VO+5?>C<HJ&W
MNK>[3?;7$4RC^*-PP_2IJLYVFG9A69=:M-:3LC:/J,D2G`FA6-U;C/"A]_YK
M6G12:;V*A*,7[RN8(\9:$CK'=7;V4A*@I>P20$$]OG`'ZUK6NH65\NZTNX+A
M<9S#('&/P-3NJR(R.H96&"I&016'>>"_#E]())M(MED#;M\`,+9SG.4P<YJ/
MWB[/\/\`,Z%]4EOS1^Z7X>[^9NT5R3>#;RUYT?Q1JMIC&$G87,:X]%;\>_?V
MJK))\0]*7/E:7K,>.J9BDX'4@X7UZ9_"DZC7Q1?YFL<%3J?PJT?1WB_QT_$Z
M*\\-Z/?W#7$UC&+AOO3PDQ2-TZNA#'H.]56\/7]N/^);XCU"'G[ET%NE[_WQ
MN[_WJP_^%F16$@CU_0=2TMR<!BF]._\`%QGIV![^E;^G^,?#NJ8%IK%JS'HD
MC^6QZ_PM@]C4*=&3T>OW,VG0S&A'WXMQ^4H_JBD]WXSTX9DT[3M6C7O;3&"0
MCCDJ^1GJ>#^50'XB:=:2"+6;#4])?^]<VQ*'KT*YST]/ZUV%-DC26-HY$5T8
M8*L,@U;A)?#+[]3GCB:$M*U)>L6XO]5^!1T[7=)U<?\`$OU&VN6`R5CD!8?5
M>HZ5H5RNJ_#OPUJK&0V/V28G/FV9\LC\/N_I6)+X4\9Z$H;0/$C7D2_\NUZ`
M3VX!;([?[.*ESJ1^*-_3_(VCA<'6_A5N5]IJW_DRNOO2/1:*\S_X61KFA2)%
MXI\.20J3M\^#@$CKC.58X]&_G74:3X\\.:R%6#4HXI2/]5<?NV^G/!/T)IQQ
M%.3M?7ST)KY3BZ,>=PO'O'WE]Z.DHHHK8\T****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"HYK>&Y0
M)/#'*H.0KJ&&?QJ2B@:;3NCGKGP-X:NG#G28(9%.5>VS"0?;815*3P3=6_.D
M^*-8M,#`CEE\^-?3"M^/?O7745FZ,'T.N&88J.G.VNSU7W.Z.)DB^(FFIF&Y
MTG5U':6,Q2'J>V%]!U_QJ%O'FLZ6<:[X1OH47[T]JWFK_A_X]7>45/LI+X9/
M\S98^E+2M1B_2\7^&GX''V/Q.\+7H&Z^>V<C.VXB*_J,C]:ZBTO[+4(_,LKN
M"Y0=6AD#C\P?8_E5'4_#.B:P6-_I=M,[<&0IA^_\0P>_K7(:A\(=+<^;I5_=
MV,X.5R?,4?R;]:ENO'HG^!K&&5UMI2IOS2DOPL_P/1:*\H?1_B7X=YLM2_M.
M!?X2XD./I)S^1[TVV^+>HZ?,MMK^A-'*/O%-T3`<\[&Z]NX[TOK45I--&O\`
M85:HN;"SC47D]?N=CU>2-)8VCD171A@JPR#7+:K\./#&J@DV`M)#_'9GR\?\
M!^[^E-TOXD^&-3VK]O\`LDA_@NU\O'_`ON_K750S17$*S02I+$PRKHP8'Z$5
MI^ZJKHSBMC<OG]JF_FO^'/+W^'_BKP_\_AGQ"[QJ=PMY&*<Y_NG*-^..]0_\
M+#\6>&F6'Q+H?FKG:)L>46(ZX891OPQ7K--DC26-HY$5T88*L,@UG]6Y?X<F
MOQ1VK.55TQE*-3SMRR^]''Z1\3_#>J;4EN7L9C@;;I=JY_WAD8^I%=?#-%<0
MK-!*DL3#*NC!@?H17':W\,/#NK!G@@.GW!Z/;<*?JG3'TQ]:X:Y\"^,?",[W
M>AW4EQ$N3NM&(<C_`&HSU^@W5+JUZ?QQNO(VC@LLQG^[U73E_+/;[_\`AV>U
MR1I+&T<B*Z,,%6&0:XO6_A=X?U4-);1-I\Y.=UO]S\4/&/IBN0T?XOZC:.+?
M6[%+@)\KR1#RY`?=>A/L-M>C:'XST+Q!M2ROE$[?\N\OR2?D>OX9IJK0KJS_
M`!,ZF!S3*I>TA=+O'5?/_@H\YE\.^//!),FD7DE[8IR5A.]0/>)NA]USQW%:
M&B_&*,D0Z[8-&X.#-;<C\4/(_`GZ5ZK6%K_@_1?$B$W]H!/C`N8OED'X]_H<
MBD\/.&M*7R>QI'-L+BO=S"BF_P":.DOGW_K0O:7K6FZU;"?3;V&YC(YV-ROU
M7J#]15^O$-7^&OB'PY<_;]"N)+M(SE6MR4G3_@(Z_AG/H*M^'OB[>6A6VU^W
M-R@.#/$`L@^J]#^GXTHXKE?+65G^!57(%6A[;+JBJ1[;27]?+T/9**H:1K6G
M:[9BZTVZCGC_`(MI^9#Z,.H/UJ_76FFKH^=G"5.3A-6:Z,****9(4444`%%%
M%`!1110`4444`%%9U]KVD:9D7NIVD##/RR3*&X]LY-4U\4VMP<:?8ZE?Y.`T
M-JRH>0/OR;5[YZ]*ESBG:YO'"UI+F47;OT^_8W:*9#(TL*2/"\+,,F-R"R^Q
MVDC/T)I]48M6=@HHHH$%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!5>]L+/48#!>VL-S$?X)4##]:L44-7W'&3B[Q=F<%J_PET"_W/8M-I\I
MR1Y9WID_[+<_@"*XN[\!>,?"TCW&C7,T\0&XM92E7(]"F<GIT&ZO<:*YIX2E
M+5*S\CVL-Q!C:*Y)RYX]I:_CN>(:?\5_$6E2_9M7M8[LIPRRIY,H^I`QT_V:
M[O1OBAX<U7"33O83$@;;D84_1AQCZXKH]5T'2M;B\O4K&&X&,!G7YA]&'(_`
MUYUKGP<C8&70[XHV?]1=<C\&`R/Q!^M9..)I?"^9'?&ODN.TK0=&7=;?Y?@O
M4]3BECGB66&19(W&5=&R"/8T^OG!X_%?@6Z!)N]/W-PRG,4A_56Z=*['1/C'
M*I6+6[$.O_/>VX/XJ>#^!%.&-@W::LS/$\,8B,?:862J1\M_\ON9Z-K?A?1O
M$*8U*QCE<#"RC*NO_`AS^!XKRWQ%\(]0LM\^B3?;H!SY,F%E4?R;]#[5ZIHO
MB72/$$(DTV]CE;'S1$[9%^JGG\>E:U:U*%*LK_BCAPN:8_+9\B;5OLRV^[I\
MK'@&D?$'Q-X:G%G=M)<10G:]M>*0Z>VX_,/H<@>E>I>'?B)H7B#9%YWV.\;C
MR+@@9/\`LMT/\_:MC6_#>D^(8/*U*SCF(&$DZ.GT8<CZ=*\C\3?"G4M+$ESI
M#-?VH.1$!^^4?0?>_#\JYW'$4/A]Y'L1JY3FVE5>QJ/JMG^GWV?F>XUS/B7P
M+HWB9&>>'R+S!VW4(PV?]H=&'UY]"*\B\._$+7?#<JV\SM=VD9VM;7!.5QV5
MNJ_3D>U>Q>&_&>C^)XP+2<1W0&7MI3AQZX_O#W'XXK6G7I5URO[F>?BLJQ^4
MS]M3>B^U']?ZL>.ZMX>\2?#[4!>6T\BP@C9>6_W&]F']#P?>N^\(?%&TU4K9
M:V8[.[QA9LXBD/O_`'3]>/Y5Z%+%'/$T4T:R1N,,CKD$>XKRKQA\*1M>_P##
MBX(RSV3'K_N'_P!E/X>E92HU*#YJ6J['=2S+!YK%4<P7+/I-?K_5O0]8HKQ+
MP1\1+G0ITT?7"[62L4$C@^9;G/0]RH.>.H_#%>UQR)+&LD;J\;@,K*<A@>A!
M]*ZJ->-6-T>%F665LOJ<E35/9]'_`%V'445@:UXTT#0=RWNH1F9?^6$7SOGT
MP.GXXK24HQ5Y.QQT:%6M+DI1<GY*YOT5Y'J7Q@N[J7[-H.E8=R51Y\N[9Z81
M>_XFH8?#/C_Q</,U?4);*TD',<K[,C_KDN/_`![%<_UJ+=J:<CV5D%6G'GQD
MXTEYN[^21Z/J7B_P_I!(O=6MD<=41O,8?\!7)KF6^*45],;?P_H6H:E,#C[N
MU1GOQN./KBK&C?"KP_IA62Z634)@/^6YPF?91_4FNTM[:"TA6&V@CAB7A4C0
M*H^@%4E7ENU'\3&<\LH:4XRJONWRK[EK^*.+B_X6)JY)=M.T2+C'RB:3'TRP
M_/'6K<?@1+E?^)WK>J:H<8,;SF*(\8/RJ>_/>NCO]4T_2XC)?WL%L@&<RR!<
M_3/6N.U+XM>';,E;7[3?/ZQ1[5_$M@_D#2DJ4/XDK^K_`$-*$\?B=,)2Y5_=
MC;_R9Z_B=7IN@:1I`4:?IMM;L!C>D8WGKU;J>IZFM&O*HO''C;Q(<:#H*00L
M>)G4L!_P-L+^E6X_!'B[6?WFO^*985)R8+8DC\0-J@_@:(UTU:G%O\$%7*YP
MES8VO&+]7*7W*_YG=7^NZ3I9(O\`4K2W8#.R250Q^@ZGJ/SK`D^)&A-.8-/2
M^U.4'!2RMF<]??&?PI=,^&GAC32&-B;N0?Q73[__`!WA?TKJ;>V@M(5AMH(X
M8EX5(T"J/H!5KVSWLOQ_R.63R^G\*E-^=HK[O>?XHYJ/7?%%^%^Q^%Q;(V/W
ME_=A,<\_(H+?YZ5.EAXLNES=ZW8V9V@;;&SW<^NZ0GZ=/RKHZ9++'!&9)9%C
M0=6=L`?C5>S_`)F_R_(R>+5[4J<5\N;_`-*N9=OH`CN$GGU75;IT;>!)=%%S
MD'E8PJD<="".O%:]<_>^.?#&GG$^M6I(ZB%C*1_WQFLC_A9VFW+-'I.EZMJ<
M@'_+O;97\><CCGI4^UI0TN:?4<=B%S.F[>EE^B.WHKDDUOQA??\`'KX7@LT)
M($E[>`\9QDJHR/7^56([+QC<A?M6L:99\886=HTA_`R-U]\?A5*K?9/^O6QG
M+!.'\2<5\[_^D\QTM%82>'KMR&N_$>JS/M*D1M'"I_!$!S[YK3L;"+3X3'%)
M<R`G)-Q<23-GZN3CZ#BJ3;Z&%2G3BM)W?DG;\;?D6J***HQ"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`(Y[>&Z@>"XACFA<8>.10RL/<'K7`>(OA-
MI>H[Y])?^S[@\^7C=$Q^G5?PX]J]#HK.I2A45I(Z\)C\1A)<U";7Y?-;'S1K
M'AK7/"UTKW=O+!M;]W<Q$E"?9AT/Y&NB\/?%;6=+*PZD!J5MGJYVRK]&[_B#
M]17N4L4<\3131K)&XPR.N01[BO._$WPFL-0WW.B.+&XQGR",Q.?;NOZCVKAE
MA:E)\U%GU=#/\%CXJCF5->O3_-?(ZK0/&&B^)$`L+L"?&3;2_+(/P[_49%;M
M?+VJZ-JGAZ^6"_MY+:<'<C9X..ZL.#^%=AX9^*VIZ7LMM7#:A:@X\PG]\@^I
M^]^//O54L=KRU59F..X6;C[;`RYXOI_D]F>E>)_`FD>)T,DL?V:\'2YA`#'_
M`'A_$/KSZ$5XKX@\*ZUX0O5>=6$8;,-W`3M/IS_"?8U[]HOB#2_$%H+C3;M)
MEQ\R='3V93R*O7-M!>6TEO<Q)-#(-KQNN0P]Q6M7#4ZRYH[]S@R_.\7ELO8U
MDW%;Q>Z].WIL>1^$/BO+`8['Q#F6+A4O%'S+_OCN/<<\=\UZY;7,%Y;1W%M*
MDT,@W)(C9##V->1^,OA7+;E[_P`.HTL1.7LNK)_N'N/;K]>W)>%?&>I^$[O;
M&S2V;-^^M'/!]2/[K>_YYK"&(J4)<E;;N>KB<HPF:4GB<M=I=8[?AT?X/\3U
MKQMX!LO$D#WEN5MM3C0[9.B2>S_X]O?I7G/A?X@ZAX1AN-,NH1>VZ9$4?G#]
MT_LPR"OM^7>JNM^+_$/C:[6QA1UA<X2RM@3N]V/5OQX]A6_IGP<O9],DEU"]
M2VO&3]U`H#!6[;V'],_CTK.4I5*G/AU\SJHT*6"P?U?-ZB:=K1W:^:U_1=S&
MO?%WB[QG>FTL?.5&Z6UD"H`]6;K^)./I70Z!\'9&*3Z]=A%QDVUL<GZ%^@_`
M'ZUT?PO-[;Z-=Z9?Z8UI+93;/,,002YSW'WB/7G((K9U[QMH7ATE+V[#W`_Y
M=X!OD_$=!^)%:TZ,'%5:SOZG!B\SQ-.M+`Y=344OY=6_._\`3\R]I'A[2=!A
M\O3;&&#(VLX7+L/=CR:L7^IV.EP^=?WD%M'@X:60+G'IGJ?I7C>N?%S5[X-%
MI<*:?"01OSYDA_$C`_+\:QM+\)^)_&%R+ITG:.09-Y>,0I'L3RP^F:IXN/P4
M8W,H\.UFOK&8U5!=;N[^_;\ST+6/C!H]JK)I=O-?2X^5V'EQ_K\WZ#ZUR#>-
M/''BNX>WTL21JPP4L8MNT>[GE?KD5V>A_"31K!4DU2234+@<E22D0/T')_$X
M/I7>V]M!:0K#;01PQ+PJ1H%4?0"FJ5>IK4E9=D1+'Y3@M,)2]I+^:6WW?\!'
MD.E_"/5-0F%UK^HB$N-SHC>;*3Z%CP#[_-7?:/X"\.:*%,.GI/,!_KKD"1OK
MSP#]`*W+[4+/3+9KB^NH;>%1R\KA1_\`7-</JWQ=T.R+)I\,^H2`]0/+C_,C
M/_CM7[/#T-7OY[G.\7F^:>[3OR]HZ1^__-GH-17%S!:0M-<SQPQ+RSR.%4?4
MFO#=0^*/B?5I%M[`1VF\@*EM'OD;VR<_H!19_#_Q?XFG^U:H\D`(SYM_(2Y]
M@O)'T.*GZYS.U*+9JN''1CSXZM&FOO?Z?A<])U/XE^&--)47QNY!_#:IO_\`
M'N%_6N4N_C#<W,P@T71"\C'"&9BY;_@"_P"-;&D_"+0[(J^H33ZA(#T)\N/\
M@<_^/5VUAIECI</DV%G!;1X&5BC"YQZXZGZU2CB)_$U$RE6R;#:4H2JONW9?
MAK]Z/,HXOBCXB7YIAI=NXR-VV'''L#(*OV_PF6ZF6XU[7;R_DZD*<?AN8DD?
ME7I-1SW$-M$9;B:.*,=7D8*!^)JEAH;S;?JS"6=XGX</&--?W8J_WZLP=-\"
M^&M+VF#28'=?XYQYK9XY^;.#QVQ70HJQHJ(H55&`H&`!7+:C\1O"^G9#:FMP
MX_@ME,F?Q'R_K7*7_P`:(`"NG:1(_/#W$H7'_`5S[]Z'6H4M$TO04<MS7'/F
ME"3\Y?\`!/5:*\17Q[XZ\0NRZ3;%5S@_9+7>%]BS;L=?:K47@KX@:YSJFJR6
M\3')2>[9NV.$3(SCZ5*Q?-\$6SHEP^Z/^]5X0\KW?W'K-WJNG6&?ME_:VV.O
MG3*G\S6#=?$7PI:9#:O'(P!($,;OG';(&/UKF]/^#.G1%6U#4[FX(Y*PH(P?
M;G)QU]/PKI[#X?\`A?3POEZ1#,PZM<9ES^#9'Z52EB)=$OQ,)4LII;U)U/1*
M*_&YCR?%O1&=HK*QU*[EQE1'",'_`,>S^E3IXR\27C%;'P1>C((5KJ80X.,\
MAE''X\UV4%M!:Q^7;P1PQYSMC0*/R%2U2A4>\ON7_#F$L5@H_P`.A?\`Q2;_
M`"Y3D8[KQ]<["NG:)9#&6^T2O(?H-AZBK4>G^+9)&>?7M/A!/"0V!88^K/G^
M==)15JGW;^__`",98U_8IQ7_`&[?_P!*N8<6C:N'8S^*+YE/01VUNN/SC-7M
M/TY[$R&34;R\:0Y)N64X^@50!^%7J*I02,9XB<U9V^22_)(****HP"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`J:CIEEJUHUIJ%M'<0,<E)!G!]1Z'W%>0
M>*_A1=Z>'O-"+WEN"2UL1^]0?[/]\?KTZU[516-:A"JO>/2R[-L3@)7I/3JG
ML_Z\CY6L;^]TF]6YLKB6VN(SPR'!'L?4>H->N>$OBM!>M'9:^([:<_*MVO$;
M?[W]T^_3Z5O^+?A_IGB9'N$46FI8XN$'#GT<=_KUZ=ABO#M<\/ZEX=OC::C;
MF-OX''*2#U4]^OX5YKC6PKNM4?:TZV79_3Y)KEJ+[UZ/JOZL>Q^./B);^'T>
MPTXK/J3I]X$%(,]"?4XY`^F??SC1?`_B#Q@+C5&(1)=T@N+DD>>^3T_'OTK!
MT*\L-/UFWN=2L!?6B'YX"V,^_OCK@\&OHBV\3Z)/H/\`:\=]"E@H&YVXV'IM
M(Z@^WY5I!K%2<JCLET.3%1GD5&-+!T^:4MYM7U[)?DOS9\_Z;J6K^#/$#.BM
M;W<#;)H)!PX[JP[@^OT(KV(?%/PZ-$BOWED^T.,&S5<R*PZCTQ[]_P!*\W\?
M^,K/Q5=1):6"QQVY(6ZD'[UQSQQP%[X.3].17%UA&O*@W&F[H]6KE5+-*=.M
MBX.$^MG^#_JZV.S\1_$K7-<,D-O*;"R)($4!P[#_`&GZGZ#`]JK^&_`.M^)B
M)UC-M:,<FYN`0&SW4=6_E[UZ-X&\#>'(].MM71QJ<LJ!E>91LC/<!.0&!XY)
MP17?3W$-K`\]Q-'#"@R\DC!54>Y/2NF&%E4]^M(\/%9]2P:>%RZE9K2[77TW
M;]?N.3T#X;:!HA29X3?72C_6W(!`/J$Z#\<D>M=>2%!)(``R2>U>>>(?BUI6
MGAH=(C-_<8_UARL2_CU;\/SKR_7?&>N^(G87MZRP'_EVA)2,#Z=_QR:TEB:-
M%<L%?T.2CD>9YE/VN*DXKO+?Y+I^![/KGQ&\.Z+OC^U?;+E>/*MOFY]"W0?G
MGVKSG6OBUKE^633DCT^$@C*@/(?^!$8'X#\:RO#_`,/-?U]5F2`6EJ>1-<Y4
M,/\`9&,G^7O7J.A?"[0-(VRW2'4K@#EKA1Y>?9.GYYK)2Q-?;W4=LJ6295\?
M[V:Z;_ALOG=GD6GZ#XD\6W/G0PW5X3PUS.YV@9_OL>>_`YKT'1/@Y;Q%9=;O
MC.P_Y86WRK^+'DCZ`?6O4D58T5$4*JC`4#``JKJ&J6&E0>=?WD-M'V,K@9^G
MK^%;0P5.'O3U/.Q/$N-Q#]EAER+HEJ_O_P`DB'2M!TK1(O+TVQAMQC!9%^8_
M5CR?Q-:->;:S\8=+MMT>DVLMZXZ22?NX_P!?F/Y"N`U;XC>)M7#(U^;6(_\`
M+.T'EC\_O?K3GC*--6CKZ$X?AW,<9+VE7W;]9/7[M_OL>[:IX@TC14W:EJ$%
MN<9",V7/T4<G\!7#:K\8],@+IIEC/=L!@22GRTSZ]R1^`KS/2?"FO^(G,ME8
M32HS?-/)\J$GJ=S=?7C)KO\`1_@TN%DUG4B3WAM5_P#9V_P_&L?;XBK_``XV
M1Z#RK)\O_P![J\\NR_R6OWLYC5/BEXFU!B(;B.QB)^Y;QC..V6;)S],54M?"
M7B_Q+(+A[2\ER?\`7WDA7\<N<D?3->XZ3X5T/0PIT_38(Y!_RU(W2?\`?1R:
MV:M8.4]:LKF,N)*&'7+@*"CYO?\`#_-GDVE_!C[KZMJOUBM$_P#9V_'^&NUT
MSP%X:THJT.EQ2R*<B2X_>'/_``+@?@*Z2BNB&&I0V1XN)SK'8G2I4=NRT7X?
MJ(BK&BHBA548"@8`%+116YY84444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!5#5]&L-=T][+4+=987]>"I]5/8U?K
MFO&?B^V\)Z:)&42WLP(MX>Q(ZLWL,CZ_J(J.,8MSV.C"4ZU2M&&'OSWTL>+^
M-/"$OA+44B^T)/;3@M"V1O`!Z,OKTYZ']*YK)QC)P3DBNBT_2M>\>Z[+,NZ:
M5VS/<R<1QCMD]O91Z<"M?Q?\-;WP[;)>V4CWUFJ#SW"8:-AU)`_A[Y[=_4^'
M*DY7G"/NGZI1QU.@Z>%Q55.JU^/Z>6U^Q:^''@K2?$*O?:A>K/Y+8:PC)4CT
M+GC@\_=_/J*]#\6^"-,U[11%''!8SVJ'[/,BA$0==K`?P_RZ^N?!]'UB]T+4
MHK^PE,<T9_!AW5AW!K7\2^.M9\3,8YYO(L^UM"<+_P`"[M^/X5M2KT8TG%QU
M_,\S'95F-;'QK4ZUH+5?W?*W6_Y;^=KPKXYO?!L5_9+%'=QN?W:F3*)(#@L"
M.H(].N!S6+KOB75?$=SYVHW3R*#E(5.(T_W5Z#Z]:L>'?!^L>)Y@+&W*VX.'
MN9?EC7\>Y]AD\U['X8^&^C^'_+N)E^W7Z\^=*/E4_P"RO0?4Y/TI4J5:M%1O
M:)ICL=EF75I5G%2K/MO_`)+\_4\K\._#O7?$&R7R?L=FW/GW`(R/]E>I_E[U
MZSX=^'>A>']DOD_;+Q>?/N`#@_[*]!_/WKK:Y+Q%\1-"\/[XO.^V7B\>1;D'
M!_VFZ#^?M7=##T:"YI?B?*XC-\RS6?L:*:3Z1_5_\,CK:YW7?&^@^'LI=W@D
MN!G_`$>#YWX[$=!^)%>/:_\`$G7];#PI,+&U8_ZJV)!(]"_4_A@'TKFM.TN^
MU:Z%MI]K+<3'^&-<X]R>P]S6-3'W=J2/1P?"?+'VF-G9=E^KV_K<[G7/BYJ]
M\&BTN%-/A((WY\R0_B1@?E^-<-)+J&LWX+O<WMY*<+G=([>P[_A7I7A[X/3.
M5GU^Z$:YS]FMSEC_`+S=!]!GZBO3-(T#2M"@$6FV44`Q@N!EV^K'DU"PU>MK
M5=OZ['54SK*\L3IX*"E+NMOG)ZL\<T/X3ZWJ0674&33H"`</\TA_X".GXD?2
MO2M$^'?AS1`KK9B[N%.?.NL.?P'W1CUQGWKJZ*[:6%I4]E=GS6-S['8O24N6
M/9:?\%B`!0````,`#M2T45T'C!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`5-4U"+2=*NM0
MG5FCMXFD94&2<#H*\4T?0-6^)>OW&JW\K06>[#R@$@`=(XP?\C.3DG!]TDC2
M6-HY$5XW!5E89#`]01Z562.QT;3-J+#:65LA/9411R37/6H^TDN9^ZNAZV79
MD\%2FJ,?WLM%+LO)=QNF:78:'IZV=A`EO;Q\X'<]R3W/N:\W\9_%-(_-T[P^
MRR,1M>](!4>H0'@^F3^'K7-^.?B%<>(I)=/T]FATD''3#3X[MZ#T'XGVR?"O
M@K4_%4X,"^19*V)+IQE5]0!_$?;\R*Y*N)E)^RH(^CR_(Z="/U[-)>=G^O=^
M7YG.*K-G:I.!DX'05/8SQ6M]!//;)<Q1N&>%R0'`[$BOH[0/".D>'=/:UM;9
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M+'Z_3WKO_#'PGU#4"ESK;-8VV01"`#*X_P#9?QR?:O7-(T/3=!M/LNFVJ01D
MY;')8^I)Y)J(86K6?-4=CHQ.>8#+(>PP45)^6WS?5_U<\U\.?"`D1W'B"X(S
M@_9(&Z>S/_A^=>GZ=I=CI-J+;3[6*VA'\,:XS[D]S[FK=%>E2H0I+W4?&8[-
M,5CI7K2T[=/N_IA1116IYX4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`-DD2*
M-I)'5(T!9F8X"@=23Z5X+X^\=S>)+EK&R9H]*B;@9YG(_B;V]!^/7IT?Q8\7
M$'_A'+&4CHUXR_F(\_J?P'J*D^'GPZ$(CUG7(`9"-UO:R#[OHSCU]!V[\]//
MKSG6G[&GMU/K\JPU#+<.LQQB]Y_`NOK_`%LM>IE>!OAI+JGE:GK:/%9'#Q6_
M1IAZG^ZOZGVZGV:""&UMX[>WC6*&-0J(@P%`Z`"I*\N\;?%!;5GT[P]*LDPR
MLMV!E4.>B9X)]^GIGMLE2PL+O_@L\ZI4QV>XGECMV^S%>?\`5WT['3^+?'>F
M^%HC$2+G4"/EMD;D=.7/\(P?QKPW7_$VJ>);O[1J-P6"D^7"G$<8/]T?U.3Z
MFLPF6YG))>6:5LDG+,[$_F237J7@WX5&4)?^(T95(RED&P3[N1T_W1SZ]Q7!
M*I5Q4N6.W];GUE'"9?D-'VM5WGWZORBNG]79Y68W6-7*,$8D*Q'!QUQ7L_PE
ML-#FT5KV&U5M5BD*3R2'<R]U*_W01Z>AKI?%OA&U\0>&SIT$4,$UN-UF54*L
M;`?=XZ*1P?P..!7EOPOU2;1O&9TV<,B7@,$B'^&1<E21Z@@K_P`"JX4OJ]:/
M-JF<N)S!9QEE5TKQE#5J^Z_5-?BCW>BBBO6/S\****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`\]\.?#A[3Q#=:SK]Q%?7/GF2`*#M))SO8'OZ#H
M/?BO0))$BC:21U2-`69F.`H'4D^E*2%!)(``R2>U>(_$;QX=9G;2=*G/]FQG
M$LB\>>P/KW4?J>>>*Y9RIX:&G_#GN8>CB\[Q*4GHEJ^D5Y+]!_CSXD-JX;2]
M%>2*R!(EG^ZTW/0>B_J?;OPNEZ5?:U?I9:?;O/._\*]`/4GL/<U:\.^&]1\3
M:A]DL(P=HS+*W"1CU)_IU-?0/AGPMIWA?3Q;V<8:9@/.N&'SRGW]!SP.WZUP
MTZ53%3YY[?UL?68S'83(J'U?#J\^WZR_K\#(\'?#ZP\,QK<W`2[U,CF8CY8_
M9`>GUZ_3I79445ZL(1A'EBC\_P`3BJV*J.K6E=L*\K\?>%;Z#Q7IOB#1+*2>
M:2=#+'$,XE4@JWL"!R>@QD]:]4HI5:2J1Y6:X#'5,%5]K!7T::>S3[A1116A
MQ!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%<_P",_$:^&?#D]ZN#
M<O\`NK=3WD/0_0<G\,=ZF4E&+DS6A1G7J1I4U=MV1Q?Q3\:&!9/#NGR$2.O^
MF2J>BD?ZO\003[<=S7G/AKPU?>*-46SLUVHN#-,P^6)?4^_H._YFH=*TN_\`
M$NMI:6X:6YN'W22-R%!/S.Q]!G/_`->OHGPWX=L_#.CQV%IEL'=+*PPTC]R?
MZ#L*\NG"6*J<\OA_K0^]Q6*HY!@UAJ&M1_US/]$/T#0+'PYI<=A81[47EW/W
MI&[LQ]:U***]5)15D?`5*DZLW.;NWNPHHHID!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`5X+\3M9DUOQA]@M]TD=E_H\:+\VZ0GYL`=
M\X7'^S7N\K.D+M''YCA253.-Q[#/:O*_AOX/NVUBZU[7(&6>*5ECCF3YC+G+
M28]L\>Y)["N3%1E4Y:<>I]#D%6CA/:XVKO!62ZMO^OQ.K\!^$$\+:1F=5;4;
M@!KAQSM]$!]!^I_"NLHHKIA!0BHQ/%Q.)J8FK*M5=Y,****HP"BL?7/%>@^&
MD5M9U:TLBPW(DL@WL/4+U/X"N+G^//@.*9D2^NYE'22.T<*?^^L']*`/3**\
MQC^/?@1Y%5KN\0,0"[6K87W.,G\A74:)\0_"/B*1(M,U^SEFD.U(7<Q2.>>`
MCX8]#T'\Z`.FHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**P_&<\UKX%
M\0W%O+)#/%IER\<D;%61A$Q!!'((/>OCS_A._&'_`$->N?\`@QF_^*H`^WZ*
M\=_9]UK5=:T+69-5U.\OWCN45&NIVE*C;T!8G%>G>)=2FT;PKJ^J6ZQM/964
MUQ&L@)4LB%@#@@XR/44`:E%?,'_#1WC#_H&Z'_WXF_\`CM>G_!_XCZQ\0/[9
M_M:VL8?L/D>7]DC=<[_,SG<S?W!TQWH`]0HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHKQW]H+6M5T70M&DTK4[RP>2Y=7:UG:(L-O0E2,T`>Q45\0?\)WXP
M_P"AKUS_`,&,W_Q5?6OPVN[F^^'.A75Y<2W%Q+;!I)9G+NYR>23R:`.JHKE?
MB3=W-C\.==NK.XEM[B*V+1RPN4=#D<@CD5X]\`_$NO:SXZOK?5-;U*^@73)'
M6.ZNGE4-YL0R`Q(S@GGW-`'T71110`451UJ1XM"U"2-V1TMI&5E.""%."#7S
M-\(/%GB34_BEHUG?^(-5N[63S]\,][)(C8@D(RI.#@@'\*`/J>BBB@`HHHH`
M****`"BBB@`HHHH`****`"BO`OV@O$.MZ+KNCQZ5K&H6"26SLZVMR\08[NI"
MD9KT7X07]YJ?PMT:\O[N>[NI//WS3R&1VQ/(!ECR<``?A0!W%%%%`!1110`4
M5\L?%_Q9XDTSXI:S9V'B#5;2UC\C9#!>R1HN8(R<*#@9))_&OIG19'ET+3Y)
M'9W>VC9F8Y))49)-`%ZBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`KP3XH_'":SO+C0O"<B!XB8[C4,9PW0K'
MVX_O?EZUUOQM\;R>%/"(L;&5H]2U3=%&Z'!BC&-[#N#@@`]LYZBODZ@":ZN[
MF^NI+J\N);BXE.Z269R[N?4D\FH:[WX:?#*]^(%_([3&TTFV8"XN0,L3UV(/
M[Q'?H.O/`/TSH7PY\)>';:.*QT.S:1%VFXN(A+*WJ2S`GGT&![4`?%-:GAJ"
M2Y\5:1;PKNEEO841<XR2X`'-?;,GA[1)8VCDT?3W1P596MD((/4$8KD+[X.^
M%I?$&G:WIMN=+N[*[BNMML,12;'#;2G09QCY<8]#0!Z#1110`44R66.")I9I
M$CC499W8`#ZDU5BUC3)Y5BAU&SDD8X5$G4D_0`T`7:***`"BBB@`HHI&8*I9
MB`H&22>!0`M%5K;4;*]9EM;RWG91EA%*K$?D:LT`%%%4X-6TVYF6&WU"TEE;
M[J1S*S'OT!H`R_'?_)//$W_8*NO_`$4U?$%?;_CO_DGGB;_L%77_`**:OB"@
M#Z/_`&:_^1>US_K[3_T"O5/&<$UUX%\0V]O%)-/+IERD<<:EF=C$P``'))/:
MO*_V:_\`D7M<_P"OM/\`T"O<*`/B#_A!/&'_`$*FN?\`@NF_^)KW#]GC0M8T
M3_A)/[6TJ^L/.^S>7]KMWBWX\W.-P&<9'3U%>WT4`%%%%`!114<\\-M"TUQ+
M'%$OWGD8*H[=30!)15>UO[.]W?9+N"XV8W>5('VYZ9Q]#5B@`HHHH`***HR:
MUI44C1R:G9HZ$JRM.H((Z@C-`%ZBFQR)+&LD;JZ.`RLIR"#T(-.H`*\/_:4_
MY%[0_P#K[?\`]`KW"O#_`-I3_D7M#_Z^W_\`0*`/G"OL_P"%?_)+_#W_`%Z#
M^9KXPK[/^%?_`"2_P]_UZ#^9H`/BI_R2_P`0_P#7H?YBO$/V<?\`DH>H?]@J
M3_T;%7M_Q4_Y)?XA_P"O0_S%>(?LX_\`)0]0_P"P5)_Z-BH`^GZ***`,_7O^
M1>U/_KTE_P#0#7RA\$O^2O:%_P!O'_HB2OJ_7O\`D7M3_P"O27_T`U\H?!+_
M`)*]H7_;Q_Z(DH`^OZ***`"BBJEOJFGW<OE6U_:S2$9V1S*Q_(&@"W1110`4
M444`%%5KG4;*R95NKRW@9AE1+*JD_F:GCD26-9(W5T<!E93D$'H0:`'4444`
M?.'[2G_(PZ'_`->C_P#H=>G_``2_Y)#H7_;Q_P"CY*\P_:4_Y&'0_P#KT?\`
M]#KT_P""7_)(="_[>/\`T?)0!Z!7F_BSXU^%_"NHW&F,EY>W\!VR101;51O0
MLQ'YC/6O2*^,/BI_R5#Q#_U]G^0H`^SZ***`/D#XV_\`)7M=_P"W?_T1'7U?
MH/\`R+VF?]>D7_H`KY0^-O\`R5[7?^W?_P!$1U]7Z#_R+VF?]>D7_H`H`T**
MJOJ5A'=?99+VV6X)"B)I5#Y/08SGG(JU0`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110!\D?'+6FU?XG7L(+>5I\:6L
M8/L-S?\`CS'UZ?@/.8XWED6.-&=W(5549))Z`"MCQ?=_;_&NNW>&`FU"=P&.
M2`9&('X"KGP[LDU#XB^'K:3;L-_$[!EW!@K!B"/?&/QH`^O?!_AR#PGX4T_1
MH%CS;Q`3.@P))2/G?\3G\,"MRBB@`HHHH`*\*^.?Q$\2>&M>M=#T:\6RMYK)
M;B26-!YK%G=<;CG:,(#P`<YYKW6O*_B)\)I/'WC?3M1DO?LNGPV?D7#+R[8=
MF4(,<9WG))].*`/EZ^U*_P!4G\_4+VYNYO\`GI<2M(WYDFJM?9.B?"3P1H<.
MR/0;:[<C#2WZBX9OP;*C\`*O:M\.?"&LV36UUX>T]!L"+)!`L4B`#`VLH!&.
MPZ>U`'R5X=\=>)O"T\<FDZO<Q1I_R[N^^%AZ%#D?CC([$5]3?#3XB6OQ`T5Y
MO*2VU*U(6ZME8D#/1U)'W3@\<XQ@YZGY9\<^%Y/!WB^_T5V9XX7W02-U>)N5
M)]\<'W!KHO@EK,ND_$_3HU+>3?![691W!4E>_9@OX9H`^NZ^3/C-JVI6WQ8U
MN&WU"[BB7R-J1S,JC]Q&>@-?6=?('QM_Y*]KO_;O_P"B(Z`(OA_X]N?"_B";
M5K^[NKM(;241V\D[$22'`4<YQSW]`:P?$WC#7?%]^]WK-_)-EMR0@XBB]`J=
M!@=^I[DFL*O7/`7P+U'Q3IL.KZM>?V;I\Z;X$5-TTJD<-@X"J>H/)([`$&@"
M3]G'_DH>H?\`8*D_]&Q5[9\2/B!:>`-`6Z>,3ZA<EDL[<G`9@.6;_97(SCGD
M#OD9O@+X1Z?X!UZ;5;/4[JZ>6U-L8YD4`99&)R/=/UKP3XR^(&U[XEZD`Y-O
M8-]BB7GC9P__`(_O_2@#G?$7C'Q!XJN7FUC5+BX4L66#>1$G^Z@X';\JPJU_
M"_A^Y\5>)K#1+1@DMW+LWD9"*`2S8[X4$X]J^M])^%G@K2-/%G'X?LKD8^::
M\B6:1CZ[F''X8%`'S?X>^*FLZ9X?UC0=3GGU'3K^PFMHQ*Y9[=W1E4J3_#D\
MC\1Z'@:]=^-'POM/!\EOK6AQNFE7+^5+`S;O(EP2-I/.U@#US@@\\@#R*@#Z
M/_9K_P"1>US_`*^T_P#0*]AUQF70-2920PM92"#R/E->/?LU_P#(O:Y_U]I_
MZ!7L&O?\B]J?_7I+_P"@&@#X@_MW6/\`H*WW_@0_^->\?LWW]Y>_\)-]KNY[
MC9]EV^;(6VY\[.,_05\[U]`?LR_\S3_VZ?\`M:@#WJY@%U:S6[,Z+*C(60X8
M9&,@^M?"O]NZQ_T%;[_P(?\`QK[OKX`H`],\&_%J]\(^$M8M$,]UJ]U*AM9K
MARZ0KM(9N>I'&!T.>>F#P6KZWJFO7K7FK7]Q>7#$_/-(6QDYP!T`]A@"M?P'
MX-NO'7BB+1[:584"&:XF89\N($`D#N<D`#U(KZ-3X#>`UT[[*;&[>;&/M;7;
M^;]<#Y/_`!WO0!\GQ2R02K+#(\<BG*NC$$?0BO=_@]\7]1GUBW\-^);QKJ.Y
M(CL[N8YD63LC'JVX\`GG/<@\>:?$?P-/X"\3G3FF-Q:3)YUK,1@LA)&&[;@1
MSCV/&<5RMM<S6=U#=6[F.:%UDC<=58'(/YT`??5<1\5_%&I^$/`TVJ:2T*W7
MG)$&ECWA0V1D#.,].N1[5V%E<B]L+>Z52JSQ+(%/4;AG'ZUR_P`3/"ESXS\%
M7&D6;HET\T+QM(V$&'&XMP3@*6/'<"@#Y)UOQ=XA\1R.^KZS>78<Y,;RD1CI
MT0?*O0<`#I6+7U=X8^!'A+1(89-2A?5[U1EWN&(BW>T8XQ_O;J[,^"/";6[6
M_P#PC&C"%CN*"QB`SC&?N]<$\T`?%>FZQJ6C7'VC3-0NK*;.=]O*R$]>N#SU
M/YFOH#X3?&>YUO48?#WB9XVNYOEM;T#;YK<8C90,9/.&XSP,9KCOC5\-++P=
M-9ZOHD;1:9=N89(2Q;RI>6&"><$`\=MI]1CR>">6UN(KB"1HYHG#QNIP58'(
M(_&@#[[KP_\`:4_Y%[0_^OM__0*]BT745UC0M/U-%VK>6T=P!Z!U#?UKQW]I
M3_D7M#_Z^W_]`H`^<*^S_A7_`,DO\/?]>@_F:^,*^S_A7_R2_P`/?]>@_F:`
M#XJ?\DO\0_\`7H?YBO$/V<?^2AZA_P!@J3_T;%7M_P`5/^27^(?^O0_S%?)'
MAS2]>U?49+?P[#=RWBQ%W6U8JWEY`).".,E?TH`^YZ*^0/\`A"?BC_T#]<_[
M_-_\51_PA/Q1_P"@?KG_`'^;_P"*H`^K]>_Y%[4_^O27_P!`-?*'P2_Y*]H7
M_;Q_Z(DJ.?P9\3(K>62>PUL0JA:0M,V`H'.?F]*D^"7_`"5[0O\`MX_]$24`
M?7]<OX]\;67@3PW)J=TGG3,?+MK<,`99/Z`=2>P_"NHKY4^/GB)M7^()TU)&
M-MI40A5?X?,;#.1^:J?]R@#G;O5O&WQ3UP6V^[U&9R2EK"=D,(^G"J.GS-SP
M,DUIWWP/\=V-D;G^RX[C:,M%;SJ\@&/3//T&37OWPB\)1>%/`5D&1?MU^BW=
MT^.<L,JG_`5P,=,[CWKO*`/D_P``_%_7?"&J1V>M3W5]I(8QS03G=+!SR4+<
MY']TG'7H>:^JK2Z@OK*"\M95EMYXUEBD7HZL,@CZ@U\^?M%>$X+2[T_Q/:0K
M&;MS;79'&Z0#*-]2H8'_`'177?L^>('U3P+-I<TA>;2Y]BY()$3_`#+[]=XY
M[`8Z<`'K=?*'B?XF>//&6LRZ-8F>U'F-$+'2]Q9L$@AF'S-[]![5]7UC:'X5
MT7PY->S:78QP37LS37$@'S.2Q;'LHR<`<"@#YBM/@;X]OH?M$FGPP,YSMN+I
M-YSSD@$XZ]^?:LB^T7QQ\+M12YD6\TMF?"7,$F8I2,X&5RIXR=K<X[5]FUF>
M(=#L_$F@7FD7T:/#<Q%,LN[8V.&'N#@CZ4`<'\(_BBWCBSET_5?)CUJU4,?+
M^47$?3>!V(/4#CD$8!P/3Z^,_A=J,^A_%+0V(DC9[L6DJ8P?WG[LA@?0L/IC
MVK[,H`^</VE/^1AT/_KT?_T.O3_@E_R2'0O^WC_T?)7F'[2G_(PZ'_UZ/_Z'
M7I_P2_Y)#H7_`&\?^CY*`/,/'7P^^)6J>-]7O=)MKMM/FG+0%-1C0%<#HID!
M'Y5X]K5AJ.EZS=66K*ZZA"^V</('(;W8$@_G7WA7QA\5/^2H>(?^OL_R%`'0
M?\*O^+?_`#Z7W_@UB_\`CM?0?PTTO5]&^'VEZ?KJ2)J47F^<LDHD89E=E^8$
M@_*1WKK**`/D#XV_\E>UW_MW_P#1$=7&UKQ]\5KB+2-)CG73X(EB-O`_EPHH
M&,RN<!B1V/X"J?QM_P"2O:[_`-N__HB.OI+X:^&[7PSX#TJU@B19IH$N+EP!
MEY7`+9/?&<#V`H`\`O?V?_&UI9"XC73KI]NXP07!\P<=/F4*3]":RO"7Q#\4
M_#G6%L;AKEK."39<Z7=9&!W"YY0]^./4&OL&O!/VD/#MNMII7B2*-4G,OV.=
MA_&"I9,_3:W/O0![7H>M67B+1+/5].D\RTNHQ(AXR.Q4XZ$'(([$&BOBBR\5
M:]IMG':66K7<%O'G9''(0JY))_4FB@#[GHHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`/A7Q/;R6GBS6+:7`DAOIXWP<C(<@U
MK?#.XCMOB9X=DDSM-]'&,#NQVC]2*O\`QATAM'^*&LILVQW4@NXSC&X2#<QZ
M_P![</PKC;"]FT[4;:^MVVSVTJS1G)&&4@CISU%`'WO15+2-4MM;T:SU2T<-
M;W<*S(0>S#./J.AJ[0`4444`%9FN^(=(\-:>;_6=0AL[<'`:0\L?15'+'V`)
MJ36]6MM!T.]U:[)^SVD+2OCJ<#H/<]/QKXK\5^*]4\9:Y+JNJS;I&^6.)?N0
MIV11V'\^IYH`]\U?]HWP]:2O'I>E7NH;1Q(["%&/MG+8^H'TKG;G]I>]9E^R
M^&;>)<?,);MI"?R5<5P_PZ^%>J>/WDN5F6RTN%]DETZ[BS=U1>YQUY`&:]DL
M?V=O"%N`;J[U2[?;A@TR(N?4!5R/S-`'@GCOQE+XZ\0)J\]C#9RB!862)B0V
MTD[CGO@@?@*L_"O_`)*AX>_Z^Q_(UI?&+PAI/@KQ=::;HZ2K;RV"3L)9-YW&
M213S]%%9OPK_`.2H>'O^OL?R-`'V?7R!\;?^2O:[_P!N_P#Z(CKZ_KY`^-O_
M`"5[7?\`MW_]$1T`<GX:T^/5_%6D:;,<17E[#;N?9W"GH1Z^M?=,<:11K'&B
MHB`*JJ,``=`!7Q%X$_Y*'X9_["MK_P"C5K[?H`*^![VY:]O[BZ90K3RM(5'0
M9.<?K7WQ7P!0![#^SG8"?QY?7C("MM8-M.<%79U`X[\!J^GJ^;/V;)XU\5:S
M;EOWKV0=5QU"N`3_`./#\Z^DZ`.&^,-E'??"K7$D`S%$LR-@$AE=3QZ9P1]"
M:^.:^U/B9.UO\,_$3JJ,38R)AQD?,-N?J,Y'O7Q70!]'_LU_\B]KG_7VG_H%
M>P:]_P`B]J?_`%Z2_P#H!KQ_]FO_`)%[7/\`K[3_`-`KV#7O^1>U/_KTE_\`
M0#0!\(5]`?LR_P#,T_\`;I_[6KY_KZ`_9E_YFG_MT_\`:U`'O]?`%??]?`%`
M'MW[-D:'Q-K4A12ZV:J&QR`7&1GWP/R%?2-?.'[-?_(PZY_UZ)_Z'7T?0!\^
M?M,Q1B;PS,%`D=;E6;N0/*('_CQ_.O`Z^@/VFO\`F5O^WO\`]HU\_P!`'W?H
M/_(O:9_UZ1?^@"KLLL=O#)--(D<4:EW=V`55')))Z`52T'_D7M,_Z](O_0!7
MS9\;OB'>:YXANO#5G*T6DV$ICE1>#/,IPQ;U"G@#U&?3`!ZEX@^/7@_1W:&R
MDN-6F4X/V5,1@YY^=L9^J@BN/NOVF'*R+9^%E5L_NY)KW/&>ZA!V]_SKQCPU
MX:U/Q;KD.D:3")+F4%LL<(B@9+,>P_J0.I%>^:/^S?H<,,;:QK%]=3C!9;8+
M%'GN.0Q(Z#.0>O3/`!YKX[^+]YX\\/II-YH]K;JDZSI+'*Q*L`1TZ=&(KS:O
M>/BM\*?#'A'P1)JNE172W2SQQ@R3EAACSQ7@]`'V_P"!/^2>>&?^P5:_^BEK
MR_\`:4_Y%[0_^OM__0*]0\"?\D\\,_\`8*M?_12UY?\`M*?\B]H?_7V__H%`
M'SA7V?\`"O\`Y)?X>_Z]!_,U\85]G_"O_DE_A[_KT'\S0`?%3_DE_B'_`*]#
M_,5XA^SC_P`E#U#_`+!4G_HV*O;_`(J?\DO\0_\`7H?YBO$/V<?^2AZA_P!@
MJ3_T;%0!]/T444`9^O?\B]J?_7I+_P"@&OE#X)?\E>T+_MX_]$25]7Z]_P`B
M]J?_`%Z2_P#H!KY0^"7_`"5[0O\`MX_]$24`?7]?$'CJZ^V^/_$-P)?-5]1G
MV/ZJ)"%_0"OM^OA;Q1;/9^+M:M9"I>&_GC8KT)$C`X_*@#ZH7XU_#I5"KKX"
M@8`%E<8'_D.E_P"%V_#S_H8?_)*X_P#C=<!_PS+_`-3=_P"4W_[;1_PS+_U-
MW_E-_P#MM`$WQ;^(W@OQ9X`N=/TO6A/?+-%+#$;29=^&P?F90!\I)Z]L=ZQ_
MV:[P)XCUNR\P@S6B3>7CAMCXS^'F?K6E_P`,R_\`4W?^4W_[;77_``X^#_\`
MPK_Q#<:M_;OV_P`ZT:V\K[)Y6,NC;L[V_N8QCO0!ZA6)XA\7^'_"L2R:WJMO
M9[QE$8EI&'J$7+$>X%9/Q,\:CP+X/EU*)$DO97$%I&_W3(<G)]@`3[X`XS7R
M_P"'/#7B/XH^*Y_+E:>XD/G7M[<'Y8P3C)_D%'IQ@`D`'N.H?M%^%+?*V=CJ
M=VW&#Y:1I^9;/Z5G_P##2FC_`/0OWW_?Y*U=&_9Z\)6,49U.:]U.8`;]TGE1
MD\]%3Y@#[L>G6MO_`(4E\//^A>_\G;C_`..4`?-/A6Y%[\5=$NE4JL^MP2!3
MU&9U./UK[6KXL\-01VWQ<T>WA7;%%KL*(N<X`G``YK[3H`^</VE/^1AT/_KT
M?_T.O3_@E_R2'0O^WC_T?)7F'[2G_(PZ'_UZ/_Z'7I_P2_Y)#H7_`&\?^CY*
M`/0*^,/BI_R5#Q#_`-?9_D*^SZ^,/BI_R5#Q#_U]G^0H`^SZ***`/D#XV_\`
M)7M=_P"W?_T1'7U?H/\`R+VF?]>D7_H`KY0^-O\`R5[7?^W?_P!$1U]7Z#_R
M+VF?]>D7_H`H`T*\?_:._P"2>:?_`-A6/_T5+7L%>/\`[1W_`"3S3_\`L*Q_
M^BI:`/F"BBB@#[_HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`/$OVAO"$FH:/:>)K2(O-8#R;D*N3Y).0WT5B?\`OLFOFVOO
MN>"*ZMY;>>-9(94*2(PR&4C!!_"OE7XI?"2\\'74NIZ3%)<Z"YW;OO-:Y.-K
M^J\\-^!YY(!I_!SXLQ^&53PYKS[=)9R;>YQG[,S')#?[!))SV)/8\?2\$\-U
M`D]O+'-#(-R21L&5AZ@CK7P)6II'B36]`<MI&K7EED[F6"9E5C[J#@_C0!]U
MUF:GXATC1KFTMM0U"&"XO)D@MX2<O([MM4!1SC/?H.YKX^N/B9XVN8O+D\3Z
MF%SG,<YC/YK@U0\-:C-'XXT74;AI+B6+4+>1C(Y+/M=>,G/IB@#Z9^.\TL7P
MIOTC&5EG@23C.%WAOPY45\E5]O\`CCP\?%7@K5M%4J);F#]T68@>8I#)DCMN
M5<U\37=I<6-W-:7<,D%Q"Y22*1<,C#J"*`/KWX-/9O\`"G1?L6T*J.)0#R)-
M[;L_CS]".V*[ROC#P3\2O$/@-I(],EBELI7WRVEPFZ-FQC<,$%3@#H><#.<"
MND\2_'KQ5KMB]E9QVVE0R(5D>WR96!SG#$_+QZ`'WH`R_C1K4&M_$W47MGWP
MVH2U#[L@E!\V/3#%A^&>]9_PK_Y*AX>_Z^Q_(URL]I<6R0//#)&MQ'YL)=<;
MTW%=P]1E6'X&NC^&UR+3XE>')&4L&OXH\#_;;;G_`,>H`^UJ^0/C;_R5[7?^
MW?\`]$1U]?U\@?&W_DKVN_\`;O\`^B(Z`.?\"?\`)0_#/_85M?\`T:M?;]?$
M'@3_`)*'X9_["MK_`.C5K[?H`*^(/'.E2Z+XZUO3Y@P,5Y(5+#!9&.Y3^*D'
M\:^WZ\`_:#\#2O)%XPL8V=0BP7RJ/NXX23]0I^B^]`'#_`W7(M%^)MHD[JD>
MH1/9%F_O-AD'XLBC\:^MZ^`58JP920P.00>17H^G_'/QS862VQOX+K:,++<P
M!G_$\9^IS0!ZW^T#XDBTWP.NBI(OVO4Y5!0-\PB0[BW_`'T%'OD^E?+E;ES=
M^(/'7B'S;J:?4=1F!RQ'W44$G@#"J!D\``<UAT`?1_[-?_(O:Y_U]I_Z!7L&
MO?\`(O:G_P!>DO\`Z`:\?_9K_P"1>US_`*^T_P#0*]@U[_D7M3_Z])?_`$`T
M`?"%?0'[,O\`S-/_`&Z?^UJ^?Z^@/V9?^9I_[=/_`&M0![_7P!7W_7P!0![A
M^S7_`,C#KG_7HG_H=?1]?.'[-?\`R,.N?]>B?^AU]'T`>`?M-?\`,K?]O?\`
M[1KY_KZ`_::_YE;_`+>__:-?/]`'W?H/_(O:9_UZ1?\`H`KX5N;B2[NIKF7!
MDF=I&P,#).37W5H/_(O:9_UZ1?\`H`KY%^*7A*Z\)^.+Z*2-_L=W*UQ:2G)#
MHQR1GU4G!_#UH`[_`/9I>S&LZ^C[?MQMXC#SSY89M_ZF/]*^BZ^$M"U[4_#6
MKPZII-TUO=Q9VN`""#P00>"#Z&O4G_:.\3MIWDKIFF+=XP;C:Y'U";NOXD9[
M=J`.J_:2UFV30-(T/(-U+=?:R`>51%9.1[ESC_=-?.-:NI7FM>)KJ^UR_>XO
M9%*M=7)7Y4W':H..%'8`8Z<=*RJ`/M_P)_R3SPS_`-@JU_\`12UY?^TI_P`B
M]H?_`%]O_P"@5Z9\/IX[CX<^&WB;<HTRW0G&.5C"D?F#7F?[2G_(O:'_`-?;
M_P#H%`'SA7V?\*_^27^'O^O0?S-?&%?9_P`*_P#DE_A[_KT'\S0`?%3_`))?
MXA_Z]#_,5XA^SC_R4/4/^P5)_P"C8J]O^*G_`"2_Q#_UZ'^8KQ#]G'_DH>H?
M]@J3_P!&Q4`?3]%%%`&?KW_(O:G_`->DO_H!KY0^"7_)7M"_[>/_`$1)7U?K
MW_(O:G_UZ2_^@&OE#X)?\E>T+_MX_P#1$E`'U_7QW\8M&DT7XH:PIC*Q7;B\
MB;;@.)!EB/\`@>\?4&OL2O*_C7\/9_%^B0ZGI4/F:KIX.(E'S3Q'DJ/4@\@?
M4=30!VO@G78_$O@O2=5242//;)YQ!Z2@8<?@P-;]?(GPT^*-[\/KJ:TN;>2[
MTJ=\RV^XAXF'!9,\`^H/7`Y&*]_T[XR^`]1@$@UU+=L`M%<Q/&RY[<C!_`F@
M#O**\<\3_M"^'K"VDC\/0S:G=D#RY)(S%`/<[L.<>F!GUKT+P+K%WK_@C2-5
MOBANKJ`22%%VC.3T%`'D?[3,L@A\,PAB(W:Y9E[$CR@#_P"/'\ZU_P!F^"!?
M!.J7"JOVA]1*.V>2BQH5'YLWYFM;XZ^%9_$7@7[99Q[[K2I#<[1U:+&)`/H,
M-]%/?%>'_"WXE2_#[59Q/!)=:7>!1/#&P#(P/#KG@D`D8R,Y&3P*`/L"JFJ:
MA!I.DWFHW+!8;6%YG)..%!/]*XA?C=\/FM_-.N,IP"8S:3;@2.GW,?KCWKR/
MXG?&";QM"/#OARVN(].F<+(SI^]NFR-JA1G"YP<=3QTZ$`X#P1(\OQ'\.22.
MSN^KVS,S')),RY)-?;M?%'A.RGTWXIZ'872;+BVUN"&5<_=99U!'YBOM>@#Y
MP_:4_P"1AT/_`*]'_P#0Z]/^"7_)(="_[>/_`$?)7F'[2G_(PZ'_`->C_P#H
M=>G_``2_Y)#H7_;Q_P"CY*`/0*^,/BI_R5#Q#_U]G^0K[/KXZ^,.GW&G_%+6
MA.F!/(L\3#HR,HP1^.1]0:`/L6BO.O#WQH\'ZMHUO<7VJPZ?>[%^T6\RLNQ\
M?-M..5SG!_/%=IH6N:?XDT>#5M*G,]E.6\J0HR;MK%3PP!'*GJ*`/E'XV_\`
M)7M=_P"W?_T1'7U?H/\`R+VF?]>D7_H`KY0^-O\`R5[7?^W?_P!$1U]7Z#_R
M+VF?]>D7_H`H`T*\?_:._P"2>:?_`-A6/_T5+7L%>/\`[1W_`"3S3_\`L*Q_
M^BI:`/F"BBB@#[_HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"D90RE6`*D8((X-%%`'F'C/X->#M4M+W4X[273KF.)Y3]A<
M(CD*3RA!4?@!7RUJ5LEGJMY:QEBD,[QJ6ZD!B!G\J**`*M>Y_"+X8:!K]O%K
M.H/>236_E3+$LH6,MECS@9_A'>BB@#Z,K@/B+\-?#GBNRN=4O8)(-0MX'<7-
MLP1Y-JY`?((8<#J,XZ&BB@#Y$N8Q#=31*251V49Z\&O>/@]\,/#.MZ4FMZK;
MRWDPVX@E?]R#Z[0`3]"2/:BB@#HOC)X/TW6+C19IGGA\J*2%$@*JH4%2."I]
M:\^T/P'IMAK^FWMO=7JS6]U%+&2R$!E8$<;?4444`?4-?/?Q+\%:;J_Q!U2^
MN)[M99?*W"-U"\1(.ZGTHHH`R?"W@'2K/Q=HMU'<7A>&_@D4,ZX)$BD9^7VK
MZ:HHH`*9+%'<0R0S1I)%(I1T=0593P00>H-%%`'S?\;?AUX>\+VT.KZ/#+:O
M=2,'MU?,*G(Y4$9'WCQG`[`5Y%HME'J.LVMG,SK',^UBA`(^F:**`/KSP9\.
M/#7A;1V2QLVDEO(`MQ<3ONE=2.1D8VCD_=`KP/\`X5QH_P#S\WW_`'VG_P`3
M110!ZY\%M"M]!M]9M[6:>2*1X7VRE3@X<$C`'7`_*O2=4C$VD7L3$A7@=3CK
MRIHHH`^6O^%<:/\`\_-]_P!]I_\`$UZQ\%?#EGX?_MS[))._G^1N\U@<;?,Q
MC`'J:**`/6*^3_\`A7&C_P#/S??]]I_\3110!Z;\&?"]EH&KZG+:RW#M+`JM
MYK*1][V`KV.BB@#R?XU>'+/Q!_8?VN2=/(\_;Y3`9W>7G.0?05Y/_P`*XT?_
M`)^;[_OM/_B:**`/J72XQ#I%E$I)5($49Z\**I>)/"^C^+=*;3=9M%N("=RG
M)5HV[,K#D'_]1R***`/D7XC^%[+PAXNFTG3Y;B6W1`P:X96;J1U``[>E:/PI
M\&:9XT\1&SU1[E84*G$#A=WRNV"2#_='3'4T44`?1'B?P3H5O\,=2\/V%H+&
MP9%8BWX<E75P2S9+'*CDY.*\(_X5QH__`#\WW_?:?_$T44`?1/P\M5LO`6E6
MJ.[I"CQJ7QG`=@,X`KF?C-H%KK^D:9%=23(L4[,OE,`?N^X-%%`'CG_"N-'_
M`.?F^_[[3_XFOH_P+91Z=X(TBSA9VCA@"J7()/)ZXHHH`/'5E'J/@C5[.9G6
M.:`JQ0@$<CIFO,O@[X3L-!\77=U:S7+N]@\9$K*1@R1GL!Z444`>W4444`5-
M4C$VD7L3$A7@=3CKRIKP;X:>"M-TCX@Z7?6\]VTL7F[1(ZE>8G'91ZT44`?0
ME%%%`'G'C[X4>%?$-O?:Q+:R6FH)#)*TUFP3S6`+9<$$$YZG&3GKTKY1U*V2
MSU6\M8RQ2&=XU+=2`Q`S^5%%`'K7PF^&&@>+[1+W5GO'VH7,,<H1&P[+@\;N
MW8BOI'3=.M-(TZ#3["!8+2W0)%&I)"CTYHHH`M5X;\7_`(8>&+31[CQ#86LE
MC=C<7BMF"PN0C-DI@X^Z/NX'7OS110!\[VT8FNH8F)"NZJ<=>37UA\-?ACX;
M\.VEMK<$$MSJ,J;EFNF#&'J#L```^O)]Z**`/.]2\#Z;)\1[S4?M-XL[:N\_
MRNH`;SBW'RYZ^]?1U%%`'CGQF\+V6OZOIDMU+<(T4#*OE,H'WO<&NW^&FFPZ
M1\/M+L;=I&BB\W:9""W,KGL!ZT44`=97$_$?P'H?B_1)KG4H9$N[*!WAN8&"
MR``$[22""N>Q'KC&:**`/CNYC$-U-$I)5'91GKP:^Q/A%;):_"G0(T+$-`TA
MW>KNS']2:**`/,?B7X*TW5_B#JE]<3W:RR^5N$;J%XB0=U/I7O.EQB'2+*)2
M2J0(HSUX4444`6Z\]^,6BVVO>$;2UNGE1$OTD!B(!R(Y!W!]:**`/$?^%<:/
0_P`_-]_WVG_Q-%%%`'__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
